Chronic Lymphocytic Leukemia Clinical Trial

A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)


A Phase 3 clinical trial to examine the efficacy of duvelisib monotherapy versus ofatumumab monotherapy in subjects with relapsed or refractory Chronic Lymphocytic Leukemia (leukemia-cll/" >CLL) or Small Lymphocytic Lymphoma (SLL).

View Full Description

Full Description

This is an open-label, two- arm, randomized phase 3, superiority trial designed to evaluate the efficacy and safety of duvelisib compared to ofatumumab administered to patients who have been diagnosed with CLL/SLL whose disease is relapsed or refractory.

Approximately 150 subjects will receive a starting dose of 25 mg duvelisib BID initially over the course of 21-day treatment cycle followed by 28-day treatment cycles for up to 18 cycles or until disease progression or unacceptable toxicity (whichever comes first). After 18 complete cycles of treatment, subjects may receive additional cycles of duvelisib until disease progression or unacceptable toxicity if they, in the judgment of the Investigator, may derive benefit from continued treatment, and if the subject meets the criteria for additional treatment at Cycle 19 Day 1.

Approximately 150 subjects will receive a starting dose of 300 mg ofatumumab on Day 1 followed by seven weekly doses of 2000 mg. Thereafter, subjects will receive 2000 mg ofatumumab once every month for four months. Administration of ofatumumab will not exceed the 12 doses (within 7 cycles).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Diagnosis of active CLL or SLL that meets at least one of the IWCLL 2008 criteria for requiring treatment (Binet Stage ≥ B and/or Rai Stage ≥ I)
Disease that has progressed during or relapsed after at least one previous CLL/SLL therapy
Not appropriate for treatment with a purine-based analogue regimen (per National Comprehensive Cancer Network [NCCN] or European Society for Medical Oncology [ESMO] guidelines), including relapse ≤ 36 months from a purine-based chemoimmunotherapy regimen or relapse ≤ 24 months from a purine-based monotherapy regimen
A cytogenetics or fluorescence in situ hybridization (FISH) analysis of the leukemic cells within 24 months of randomization is required to document the presence or absence of del(17p). Note: if a sample from within 24 months is not available, it should be evaluated as part of the screening laboratory evaluation to inform stratification
Measurable disease with a lymph node or tumor mass > 1.5 cm in at least one dimension as assessed by computed tomography (CT)
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 (corresponds to Karnofsky Performance Status [KPS] ≥ 60%)
Willingness by subject to be randomized to receive either ofatumumab or duvelisib at the dose and schedule defined in the protocol

Must meet the following laboratory parameters:

Serum aspartate transaminase (AST/SGOT) or alanine transaminase (ALT/SGPT) ≤ 3 x upper limit of normal (ULN)
Total bilirubin ≤ 1.5 x ULN
Serum creatinine ≤ 2.0 x ULN
Hemoglobin ≥ 8.0 g/dL with or without transfusion support
Platelet count ≥ 10,000 μL with or without transfusion support
For women of childbearing potential (WCBP): negative serum β-human chorionic gonadotropin (βhCG) pregnancy test within 1 week before randomization (WCBP defined as a sexually mature woman who has not undergone surgical sterilization or who has not been naturally post-menopausal for at least 24 consecutive months [women ≤ 55 years] or 12 consecutive months [women > 55 years])
Willingness of male and female subjects who are not surgically sterile or postmenopausal to use medically acceptable methods of birth control from the first dose of study drug to 30 days after the last dose of duvelisib and for 12 months after last dose of ofatumumab. Sexually active men, and women using oral contraceptive pills, should also use barrier contraception
Ability to voluntarily sign consent for and adhere to the entire study visit schedule and all protocol requirements
Signed and dated institutional review board (IRB)/independent ethics committee (IEC)-approved informed consent form (ICF) before any study specific screening procedures are performed

Exclusion Criteria:

History of Richter's transformation or prolymphocytic leukemia
Uncontrolled autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenia purpura (ITP) that is uncontrolled or requiring > 20 mg once daily (QD) of prednisone (or equivalent) to maintain hemoglobin > 8.0 g/dL or platelets > 10,000 μL without transfusion support
Refractory to ofatumumab (progression or relapse <12 months of receiving ofatumumab therapy or <24 months of receiving an ofatumumab- containing regimen)
Prior allogeneic transplant (prior autologous stem cell transplant >6 months prior to study entry is permitted)
Known central nervous system lymphoma or leukemia; subjects with symptoms of CNS disease must have a negative CT scan or negative diagnostic lumbar puncture prior to randomization
Use of any of the following medications or procedures within the specified timeframe:
Use of live or live attenuated vaccines within 30 days prior to randomization
Chemotherapy, radiation therapy, or ablative therapy within 3 weeks of randomization
Tyrosine kinase inhibitor within 7 days of randomization
Other investigational therapy (not included above) within 3 weeks of randomization
Previous treatment with a PI3K inhibitor or BTK inhibitor
Ongoing treatment with chronic immunosuppressants (eg, cyclosporine) or systemic steroids > 20 mg prednisone (or equivalent) QD
History of tuberculosis treatment within the preceding two years
Ongoing systemic bacterial, fungal, or viral infections at the time of initiation of study treatment (defined as requiring IV antimicrobial, antifungal or antiviral agents)
Subjects on antimicrobial, antifungal or antiviral prophylaxis are not specifically excluded if all other inclusion/exclusion criteria are met and there is no evidence of active infection at randomization
Human immunodeficiency virus (HIV) infection
Prior, current, or chronic hepatitis B or hepatitis C infection
History of alcohol abuse or chronic liver disease (other than metastatic disease to the liver)
Unable to receive prophylactic treatment for pneumocystis or herpes simplex virus (HSV)
Baseline QT interval corrected with Fridericia's method (QTcF) > 480 ms (average of triplicate readings) Note: This criterion does not apply to subjects with a right or left bundle branch block (BBB)
Unstable or severe uncontrolled medical condition (eg, unstable cardiac function, unstable pulmonary condition), or any important medical illness or abnormal laboratory finding that would, in the investigator's judgment, increase the subject's risk while participating in this study
Concurrent active malignancy other than nonmelanoma skin cancer or carcinoma in situ of the cervix, bladder, or prostate not requiring treatment. Subjects with previous malignancies are eligible provided that they have been disease free for ≥2 years
History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months
Administration of medications or foods that are strong inhibitors or inducers of CYP3A within 2 weeks of randomization
Prior surgery or gastrointestinal dysfunction that may affect drug absorption (eg, gastric bypass surgery, gastrectomy)
Major surgery or invasive intervention within 4 weeks prior to randomization
Pregnant or breastfeeding women
Hypersensitivity to ofatumumab or its excipients

Study is for people with:

Chronic Lymphocytic Leukemia


Phase 3

Estimated Enrollment:


Study ID:


Recruitment Status:




Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?


There are 92 Locations for this study

See Locations Near You

La Jolla California, 92093, United States

Denver Colorado, 80218, United States

Altamonte Springs Florida, 32701, United States

Bonita Springs Florida, 34135, United States

Bradenton Florida, 34209, United States

Brandon Florida, 33511, United States

Cape Coral Florida, 33990, United States

Clearwater Florida, 33761, United States

Englewood Florida, 34223, United States

Fort Myers Florida, 33916, United States

Gainesville Florida, 32605, United States

Hudson Florida, 34667, United States

Inverness Florida, 34453, United States

Largo Florida, 33777, United States

Naples Florida, 34119, United States

New Port Richey Florida, 34655, United States

Orange City Florida, 32763, United States

Orlando Florida, 32806, United States

Port Charlotte Florida, 33980, United States

Saint Petersburg Florida, 33705, United States

Sarasota Florida, 34236, United States

Spring Hill Florida, 34608, United States

Tampa Florida, 33607, United States

Tavares Florida, 32778, United States

Venice Florida, 34292, United States

Crestview Hills Kentucky, 41017, United States

Boston Massachusetts, 02114, United States

Boston Massachusetts, 02115, United States

Saint Louis Missouri, 63130, United States

Hackensack New Jersey, 07601, United States

New Brunswick New Jersey, 08903, United States

New York New York, 10032, United States

New York New York, 10065, United States

Cincinnati Ohio, 45236, United States

Fairfield Ohio, 45014, United States

Nashville Tennessee, 37203, United States

Charlottesville Virginia, 22903, United States

Bedford Park , 5042, Australia

East Melbourne , 3002, Australia

Melbourne , 3058, Australia

Vienna , 1090, Austria

Wels , 4600, Austria

Wien , 1130, Austria

Bruxelles , 1000, Belgium

Bruxelles , 1200, Belgium

Gent , 9000, Belgium

Leuven , 3000, Belgium

Sint- Niklaas , 9100, Belgium

Argenteuil , 95107, France

Bobigny , 93009, France

Bordeaux , 33076, France

Caen , 14033, France

Clermont-Ferrand , 63100, France

La Roche Sur Yon , 85025, France

Limoges Cedex , 87042, France

Nantes , 44000, France

Rennes , 35033, France

Vendœuvres , 54511, France

Berlin , 10707, Germany

Köln , 50937, Germany

Leer , 26789, Germany

Rostock , 18057, Germany

Ulm , 89081, Germany

Budapest , 1083, Hungary

Budapest , 1122, Hungary

Debrecen , 4032, Hungary

Gyor , 9024, Hungary

Kaposvár , 7400, Hungary

Pecs , 7624, Hungary

Szeged , 6725, Hungary

Catania , 95124, Italy

Lecce , 73100, Italy

Meldola , 47014, Italy

Milano , 20132, Italy

Milano , 20162, Italy

Padova , 35128, Italy

Ravenna , 48121, Italy

Rimini , 47923, Italy

Roma , 00133, Italy

Auckland , 1023, New Zealand

Palmerston North , 4442, New Zealand

Barcelona , 08035, Spain

Barcelona , 08036, Spain

Barcelona , 08041, Spain

Madrid , 28033, Spain

Madrid , 28050, Spain

Pamplona , 31008, Spain

Bournemouth , BH7 7, United Kingdom

Leeds , LS9 7, United Kingdom

Manchester , M20 4, United Kingdom

Nottingham , NG5 1, United Kingdom

Oxford , OX3 7, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Chronic Lymphocytic Leukemia


Phase 3

Estimated Enrollment:


Study ID:


Recruitment Status:




How clear is this clinincal trial information?


Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.